EI
COGT icon

EAM Investors’s Cogent Biosciences COGT Stock Holding History

EAM Investors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.69M Sell
121,928
-12,367
-9% -$457K 0.54% 62
2025
Q4 		$4.77M Buy
+134,295
New +$3.78M 0.53% 80
2022
Q4 		– Sell
-337,777
Closed -$5.04M – 272
2022
Q3 		$5.04M Sell
337,777
-27,890
-8% -$382K 1.1% 3
2022
Q2 		$3.3M Buy
+365,667
New +$2.5M 0.81% 11

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

EAM Investors's COGT Position: Q1 2026 in Review

EAM Investors reduced its Cogent Biosciences (COGT) stake by 9.2% in Q1 2026, selling an estimated $457K and leaving 121,928 shares worth $4.69M. The position accounts for 0.54% of the portfolio, ranked #62.

EAM Investors first reported a position in COGT in Q2 2022 and has held it in 4 quarters since. The position peaked at $5.04M in Q3 2022. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • EAM Investors held 121,928 shares of Cogent Biosciences worth $4.69M as of Q1 2026.
  • EAM Investors sold 12,367 Cogent Biosciences shares in Q1 2026, an estimated $457K.
  • Cogent Biosciences made up 0.54% of EAM Investors's portfolio in Q1 2026, its #62 holding.
  • EAM Investors first reported a position in Cogent Biosciences in Q2 2022 and has held it in 4 quarters since.
  • EAM Investors's Cogent Biosciences position peaked at $5.04M in Q3 2022.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.